Related references
Note: Only part of the references are listed.Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study
Carlo Visco et al.
HAEMATOLOGICA (2013)
A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma
Anamarija M. Perry et al.
BLOOD (2012)
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
Zijun Y. Xu-Monette et al.
BLOOD (2012)
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies
Kian-Huat Lim et al.
IMMUNOLOGICAL REVIEWS (2012)
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Tina Marie Green et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Nathalie A. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18) (q32;q21): an aggressive disease with heterogeneous histology, germina center B-cell immunophenotype and poor outcome
Shaoying Li et al.
MODERN PATHOLOGY (2012)
Multiparametric Flow Cytometry for Identification and Fluorescence Activated Cell Sorting of Five Distinct B-Cell Subpopulations in Normal Tonsil Tissue
Malene Krag Kjeldsen et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
Paul N. Meyer et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
Gonzalo Gutierrez-Garcia et al.
BLOOD (2011)
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
Peter Friedl et al.
CELL (2011)
BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab
Javeed Iqbal et al.
CLINICAL CANCER RESEARCH (2011)
The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study
Catherine Thieblemont et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
Paul N. Meyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma
P. Ruminy et al.
LEUKEMIA (2011)
B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma
Matija Snuderl et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
Nathalie A. Johnson et al.
BLOOD (2009)
A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy
William W. L. Choi et al.
CLINICAL CANCER RESEARCH (2009)
Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas
Heidi Nyman et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations
Naoto Tomita et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP
Heidi Nyman et al.
MODERN PATHOLOGY (2009)
Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations
N. Niitsu et al.
LEUKEMIA (2009)
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Mara Compagno et al.
NATURE (2009)
LMO2 protein expression predicts survival in patients with diffuse large B-Cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab
Yasodha Natkunam et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Stromal Gene Signatures in Large-B-Cell Lymphomas
G. Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
Georg Lenz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement
Steven Le Gouill et al.
HAEMATOLOGICA (2007)
Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients
F. Amen et al.
HISTOPATHOLOGY (2007)
CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma
Kenneth S. Wilson et al.
LEUKEMIA & LYMPHOMA (2007)
Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival
Robin A. Roberts et al.
BLOOD (2006)
Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma
Latha Shivakumar et al.
CLINICAL LYMPHOMA & MYELOMA (2006)
Immunohistochemical profiling based on Bcl-2, CD10 and MUMI expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma
JJF Muris et al.
JOURNAL OF PATHOLOGY (2006)
BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma
J Iqbal et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions
LM Rimsza et al.
BLOOD (2006)
Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis
A Kanungo et al.
MODERN PATHOLOGY (2006)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma
G Wright et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
N Mounier et al.
BLOOD (2003)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
A Rosenwald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Share Paper
